Osiris Therapeutics Inc $14.29

up +0.14


29/8/2014 04:00 PM  |  NASDAQ : OSIR  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get OSIR Trend Analysis - it has underperformed the S&P 500 by 42%

Partner Headlines

  1. Osiris Stem Cells To Compliment Mannkind's Afrezza In Disrupting Diabetes ...

    GuruFocus
  2. Journal Publishes Grafix Clinical Study for Chronic Wounds

    Benzinga
  3. Osiris Therapeutics Reports CMS Decides to Package Reimbursement for Products ...

    Benzinga
  4. Osiris Therapeutics Says Trial on Grafix Met All Primary, Secondary Endpoints

    Benzinga
  5. Market Wrap for Monday, October 21: Dow Closes Down, S&P and Nasdaq Close ...

    Benzinga
  6. Mid-Afternoon Market Update: JC Penney Falls on Massive Volume Following ...

    Benzinga
  7. Osiris Legal Team Responds, Says Reviewing All of Legal-Regulatory Options, ...

    Benzinga
  8. Mid-Day Market Update: Hasbro Surges On Upbeat Earnings; Gannett Shares ...

    Benzinga
  9. Mesoblast Acquires Culture Expanded Stem Cell Therapeutic Business from ...

    Benzinga
  10. Market Wrap For October 2: Dollar Moves As Shutdown Continues

    Benzinga
  11. Mid-Afternoon Market Update: Tesla Drops on Baird Downgrade and YouTube ...

    Benzinga
  12. UPDATE: Piper Jaffray Upgrades Osiris Therapeutics, Pull-Back Offers Attractive ...

    Benzinga
  13. Benzinga's Top Pre-Market Gainers

    Benzinga
  14. Mid-Afternoon Market Update: Apple Rises Sharply On Icahn Stake, NASDAQ ...

    Benzinga
  15. UPDATE: Piper Jaffray Downgrades Osiris Therapeutics on DFU Data

    Benzinga
  16. Mid-Day Market Update: US Stocks Edge Higher; Valspar Shares Decline On ...

    Benzinga
  17. Mid-Morning Market Update: Markets Drop, Yum China Same-Store Sales Down ...

    Benzinga
  18. Benzinga's Volume Movers

    Benzinga
  19. Stocks Hitting 52-Week Highs

    Benzinga
  20. Morning Market Movers

    Benzinga
  21. Osiris Reports Strong Efficacy for Grafix to Treat Diabetic Foot Ulcers

    Benzinga
  22. Osiris Therapeutics to Hold Call on Grafix Trial Aug. 13th at 9AM EDT

    Benzinga
  23. Earnings Scheduled For August 5, 2013

    Benzinga
  24. Cell Therapy Might Be Poised For A Comeback

    IBD
  25. Osiris Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus
  26. Osiris Therapeutics Regains Worldwide Rights to Prochymal and Chondrogen

    Benzinga
  27. Chicago Bridge & Iron Company N.V, Mercadolibre Among Stocks Down on Above-average ...

    FoxBusiness
  28. These Are Four of the Hottest Biotechs in the Market Right Now

    Benzinga
  29. Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression ...

    Benzinga
  30. Health Care Sector Wrap

    FoxBusiness
  31. SBA Communications Corporation, The Ryland Group Among Stocks Hitting 52-Week ...

    FoxBusiness
  32. Arena Pharmaceuticals, Merck &, Other Stocks Hit 52-Week Highs Thursday

    FoxBusiness
  33. 'Biological Legos' Could Become a Blockbuster Innovation for Osiris Therapeutics

    GuruFocus
  34. Osiris Receives Medicare Reimbursement Codes for Grafix

    Benzinga
  35. World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance ...

    Benzinga
  36. Earnings Scheduled For May 11

    Benzinga
  37. Earnings Scheduled For March 9

    Benzinga
Trading Center